A clinical study using compartmental radioimmunotherapy (cRIT) with the anti-B7H3 murine monoclonal antibody omburtamab showed both safety and therapeutic efficacy in metastatic NB.146 Bispecific antibodies are being developed, including anti-GD2 anti-B7-H3 antibodies. Here, CD276 is linked to neuroblastoma.